Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study

Nag et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
 
*, now with p = 0.0000000096 from 27 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
In Silico study showing showing significant inhibitory potential of curcumin for omicron.
45 preclinical studies support the efficacy of curcumin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,5,10,12,18,21 (and specifically the receptor binding domainB,8,11,14), MproC,5,7,9-11,13,14,16,19,21,22,24,35, RNA-dependent RNA polymeraseD,11,20, ACE2E,12,13,15, nucleocapsidF,6,23, nsp10G,23, and helicaseH,25 proteins. In Vitro studies demonstrate inhibition of the spikeA,30 (and specifically the receptor binding domainB,38), MproC,17,30,35,37, ACE2E,38, and TMPRSS2I,38 proteins. In Vitro studies demonstrate efficacy in Calu-3J,36, A549K,30, 293TL,1, HEK293-hACE2M,17,28, 293T/hACE2/TMPRSS2N,29, Vero E6O,7,11,21,28,30-32,34,36, and SH-SY5YP,27 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants8, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells34, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress1.
Nag et al., 1 May 2022, India, peer-reviewed, 4 authors. Contact: anish.nag@christuniversity.in.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperCurcuminAll
Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
Anish Nag, Ritesh Banerjee, Subhabrata Paul, Rita Kundu
Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552
Background: Omicron (B.1.1.529), a variant of SARS-CoV-2 is currently spreading globally as a dominant strain. Due to multiple mutations at its Spike protein, including 15 amino acid substitutions at the receptor binding domain (RBD), Omicron is a variant of concern (VOC) and capable of escaping vaccine generated immunity. So far, no specific treatment regime is suggested for this VOC. Methods: The three-dimensional structure of the Spike RBD domain of Omicron variant was constructed by incorporating 15 amino acid substitutions to the Native Spike (S) structure and structural changes were compared that of the Native S. Seven phytochemicals namely Allicin, Capsaicin, Cinnamaldehyde, Curcumin, Gingerol, Piperine, and Zingeberene were docked with Omicron S protein and Omicron S-hACE2 complex. Further, molecular dynamic simulation was performed between Crcumin and Omicron S protein to evaluate the structural stability of the complex in the physiological environment and compared with that of the control drug Chloroquine. Results: Curcumin, among seven phytochemicals, was found to have the most substantial inhibitory potential with Omicron S protein. Further, it was found that curcumin could disrupt the Omicron S-hACE2 complex. The molecular dynamic simulation demonstrated that Curcumin could form a stable structure with Omicron S in the physiological environment. Conclusion: To conclude, Curcumin can be considered as a potential therapeutic agent against the highly infectious Omicron variant of SARS-CoV-2.
Author contributions A.N. conceived, designed the study & performed the experimentations; Primary data analysis & manuscript draft preparation were done by S.P. Secondary data analysis was done by RB and proof reading & manuscript finalisation was done by R.K. All authors read and approved the final manuscript. Declaration of competing interest Authors declare that there is no conflict of interest. Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.compbiomed.2022.105552.
References
Aliebrahimi, Montasser, Kouhsari, Ostad, Arab et al., Identification of phytochemicals targeting c-met kinase domain using consensus docking and molecular dynamics simulation studies, Cell Biochem. Biophys, doi:10.1007/s12013-017-0821-6
Choudhary, Malik, Tomar, Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach, Front. Immunol
Cs De Magalhães, Almeida, Barbosa, Dardenne, A dynamic niching genetic algorithm strategy for docking highly flexible ligands, Inf. Sci, doi:10.1016/j.ins.2014.08.002
Dedecker, O'brien, Fleming, Geiger, Jackson et al., The crystal structure of a hyperthermophilic archaeal TATA-box binding protein, J. Mol. Biol, doi:10.1006/jmbi.1996.0697
Desta, Porter, Xia, Kozakov, Vajda, Performance and its limits in rigid body protein-protein docking, Structure, doi:10.1016/j.str.2020.06.006
Dolgin, Omicron thwarts some of the world's most-used COVID vaccines, Nature
Du, Qian, Xue, Molecular simulation of oncostatin M and receptor (OSM-OSMR) interaction as a potential therapeutic target for inflammatory bowel disease, Front. Mol. Biosci
Fu, Tu, Ping, Zheng, Yang et al., Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors, Acta Pharmacol. Sin, doi:10.1038/s41401-020-00541-z
Greaney, Starr, Bloom, An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain, bioRxiv, doi:10.1101/2021.12.04.471236
Gupta, Vemula, Donde, Gouda, Behera et al., In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1751300
Harvey, Carabelli, Jackson, Gupta, Thomson et al., SARS-CoV-2 variants, spike mutations and immune escape, Nat. Rev. Microbiol, doi:10.1038/s41579-021-00573-0
He, Hong, Pan, Lu, Wei, SARS-CoV-2 Omicron variant: characteristics and prevention, MedComm, doi:10.1002/mco2.110
Jena, Kanungo, Nayak, Chainy Gbn, Dandapat, Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies, Sci. Rep, doi:10.1038/s41598-021-81462-7
Korber, Fischer, Gnanakaran, Yoon, Theiler et al., Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell, doi:10.1016/j.cell.2020.06.043
Kumari, Kumar, Open Source Drug Discovery Consortium, A. Lynn, g_ mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations, J. Chem. Inf. Model, doi:10.1021/ci500020m
Kushwaha, Singh, Prajapati, Shuaib, Gupta et al., Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: a molecular docking and MD simulation study, Microb. Pathog, doi:10.1016/j.micpath.2021.104954
Kutzner, Páll, Fechner, Esztermann, De Groot et al., More bang for your buck: improved use of GPU nodes for GROMACS 2018, J. Comput. Chem, doi:10.1002/jcc.26011
Li, Li, Hong, Wang, Fu et al., Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs, Briefings Bioinf, doi:10.1093/bib/bby130
Li, Nie, Wu, Zhang, Ding et al., SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape, Cell, doi:10.1016/j.cell.2021.02.042
Liu, Vanblargan, Bloyet, Rothlauf, Chen et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization, Cell Host Microbe, doi:10.1016/j.chom.2021.01.014
Marín-Palma, Tabares-Guevara, Zapata-Cardona, Flórez-Álvarez, Yepes et al., Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms, Molecules, doi:10.3390/molecules26226900
Nag, Banerjee, Chowdhury, Venkatesh, Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study, Virus. Dis, doi:10.1007/s13337-021-00654-x
Nag, Paul, Banerjee, Kundu, In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools, Comput. Biol. Med, doi:10.1016/j.compbiomed.2021.104818
Pandurangan, Ochoa-Montaño, Ascher, Blundell, SDM: a server for predicting effects of mutations on protein stability, Nucleic Acids Res, doi:10.1093/nar/gkx439
Rao, Shetty, Evolutionary selectivity of amino acid is inspired from the enhanced structural stability and flexibility of the folded protein, Life Sci, doi:10.1016/j.lfs.2021.119774
Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, World J Clin Cases, doi:10.12998/wjcc.v10.i1.1
Ribaudo, Coghi, Yang, Ng, Mastinu et al., Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptorbinding domain (RBD), Nat. Prod. Res, doi:10.1080/14786419.2021.1925894
Richards, Lim, An analysis of packing in the protein folding problem, Q. Rev. Biophys, doi:10.1017/s0033583500002845
Schüttelkopf, Van Aalten, PRODRG: a tool for high-throughput crystallography of protein-ligand complexes, Acta Crystallogr. Sect. D Biol. Crystallogr, doi:10.1107/S0907444904011679
Singh, Chauhan, Pandit, Sinha, Gupta et al., The dual role of phytochemicals on SARS-CoV-2 inhibition by targeting host and viral proteins, Complementary Altern. Med, doi:10.1016/j.jtcme.2021.09.001
Tong, Shi, Zhang, Shi, Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa, Trav. Med. Infect. Dis, doi:10.1016/j.tmaid.2021.102252
Wang, Schmidt, Weisblum, Muecksch, Barnes et al., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nature, doi:10.1038/s41586-021-03324-6
Xue, Wang, Tu, Yang, Zheng et al., Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder, Phys. Chem. Chem. Phys, doi:10.1039/C7CP07869B
Xue, Yang, Wang, Zheng, Chen et al., What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation, ACS Chem. Neurosci, doi:10.1021/acschemneuro.7b00490
Yang, Lin, Xing, Zhang, Zhang et al., Structure-based discovery of novel nonpeptide inhibitors targeting SARS-CoV-2 Mpro, J. Chem. Inf. Model, doi:10.1021/acs.jcim.1c00355
Yang, Qin, Li, Tao, Zhou et al., Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information, Nucleic Acids Res, doi:10.1093/nar/gkv1230
Yang, Yu, Chang, Liang, Tso et al., Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function, Nat. Struct. Mol. Biol, doi:10.1038/s41594-021-00652-z
Yang, Zhang, Yang, Zhang, Wu et al., Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain, Chem. Biol. Drug Des, doi:10.1111/cbdd.13847
Zhang, Wu, Wu, Yang, Chen et al., SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance, Signal Transduct, Targeted Ther, doi:10.1038/s41392-021-00852-5
Zhu, Shi, Qin, Tao, Liu et al., Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery, Nucleic Acids Res, doi:10.1093/nar/gkr797
{ 'indexed': {'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T10:11:25Z', 'timestamp': 1651399885136}, 'reference-count': 44, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 7, 1]], 'date-time': '2022-07-01T00:00:00Z', 'timestamp': 1656633600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 7]]}, 'DOI': '10.1016/j.compbiomed.2022.105552', 'type': 'journal-article', 'created': {'date-parts': [[2022, 4, 27]], 'date-time': '2022-04-27T14:56:12Z', 'timestamp': 1651071372000}, 'page': '105552', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico ' 'study', 'prefix': '10.1016', 'volume': '146', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9435-3795', 'authenticated-orcid': False, 'given': 'Anish', 'family': 'Nag', 'sequence': 'first', 'affiliation': []}, {'given': 'Ritesh', 'family': 'Banerjee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Subhabrata', 'family': 'Paul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rita', 'family': 'Kundu', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.compbiomed.2022.105552_bib1', 'unstructured': 'WHO Coronavirus (COVID-19) Dashboard n.d. https://covid19.who.int ' '(accessed January 27, 2022).'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib2', 'doi-asserted-by': 'crossref', 'first-page': '838', 'DOI': '10.1002/mco2.110', 'article-title': 'SARS-CoV-2 Omicron variant: characteristics and prevention', 'volume': '2', 'author': 'He', 'year': '2021', 'journal-title': 'MedComm'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib3', 'unstructured': 'INSACOG | Department of Biotechnology n.d. ' 'https://dbtindia.gov.in/insacog (accessed January 27, 2022).'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib4', 'article-title': 'An antibody-escape calculator for mutations to the SARS-CoV-2 ' 'receptor-binding domain', 'author': 'Greaney', 'year': '2021', 'journal-title': 'bioRxiv'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2021.102252', 'article-title': 'Tracking and controlling the spatiotemporal spread of SARS-CoV-2 ' 'Omicron variant in South Africa', 'volume': '46', 'author': 'Tong', 'year': '2022', 'journal-title': 'Trav. Med. Infect. Dis.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41392-021-00852-5', 'article-title': 'SARS-CoV-2 Omicron strain exhibits potent capabilities for immune ' 'evasion and viral entrance', 'volume': '6', 'author': 'Zhang', 'year': '2021', 'journal-title': 'Signal Transduct. Targeted Ther.'}, {'key': '10.1016/j.compbiomed.2022.105552_bib7', 'author': 'CDC'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib8', 'doi-asserted-by': 'crossref', 'first-page': '812', 'DOI': '10.1016/j.cell.2020.06.043', 'article-title': 'Tracking changes in SARS-CoV-2 spike: evidence that D614G increases ' 'infectivity of the COVID-19 virus', 'volume': '182', 'author': 'Korber', 'year': '2020', 'journal-title': 'Cell'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib9', 'doi-asserted-by': 'crossref', 'first-page': '731', 'DOI': '10.1038/s41594-021-00652-z', 'article-title': 'Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and ' 'function', 'volume': '28', 'author': 'Yang', 'year': '2021', 'journal-title': 'Nat. Struct. Mol. Biol.'}, { 'issue': '7893', 'key': '10.1016/j.compbiomed.2022.105552_bib10', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/d41586-022-00079-6', 'article-title': 'Omicron thwarts some of the world’s most-used COVID vaccines', 'volume': '601', 'author': 'Dolgin', 'year': '2022', 'journal-title': 'Nature'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib11', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.compbiomed.2021.104818', 'article-title': 'In silico study of some selective phytochemicals against a hypothetical ' 'SARS-CoV-2 spike RBD using molecular docking tools', 'volume': '137', 'author': 'Nag', 'year': '2021', 'journal-title': 'Comput. Biol. Med.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib12', 'doi-asserted-by': 'crossref', 'first-page': '2617', 'DOI': '10.1080/07391102.2020.1751300', 'article-title': 'In-silico approaches to detect inhibitors of the human severe acute ' 'respiratory syndrome coronavirus envelope protein ion channel', 'volume': '39', 'author': 'Gupta', 'year': '2021', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib13', 'doi-asserted-by': 'crossref', 'first-page': '649', 'DOI': '10.1093/bib/bby130', 'article-title': 'Clinical trials, progression-speed differentiating features and ' 'swiftness rule of the innovative targets of first-in-class drugs', 'volume': '21', 'author': 'Li', 'year': '2019', 'journal-title': 'Briefings Bioinf.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib14', 'doi-asserted-by': 'crossref', 'first-page': 'D1069', 'DOI': '10.1093/nar/gkv1230', 'article-title': 'Therapeutic target database update 2016: enriched resource for bench to ' 'clinical drug target and targeted pathway information', 'volume': '44', 'author': 'Yang', 'year': '2016', 'journal-title': 'Nucleic Acids Res.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib15', 'doi-asserted-by': 'crossref', 'first-page': 'D1128', 'DOI': '10.1093/nar/gkr797', 'article-title': 'Therapeutic target database update 2012: a resource for facilitating ' 'target-oriented drug discovery', 'volume': '40', 'author': 'Zhu', 'year': '2012', 'journal-title': 'Nucleic Acids Res.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmolb.2020.00029', 'article-title': 'Molecular simulation of oncostatin M and receptor (OSM–OSMR) ' 'interaction as a potential therapeutic target for inflammatory bowel ' 'disease', 'volume': '7', 'author': 'Du', 'year': '2020', 'journal-title': 'Front. Mol. Biosci.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib17', 'doi-asserted-by': 'crossref', 'first-page': '1128', 'DOI': '10.1021/acschemneuro.7b00490', 'article-title': "What contributes to serotonin–norepinephrine reuptake inhibitors' " 'dual-targeting mechanism? The key role of transmembrane domain 6 in ' 'human serotonin and norepinephrine transporters revealed by molecular ' 'dynamics simulation', 'volume': '9', 'author': 'Xue', 'year': '2018', 'journal-title': 'ACS Chem. Neurosci.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib18', 'doi-asserted-by': 'crossref', 'first-page': '1354', 'DOI': '10.1038/s41401-020-00541-z', 'article-title': 'Subtype-selective mechanisms of negative allosteric modulators binding ' 'to group I metabotropic glutamate receptors', 'volume': '42', 'author': 'Fu', 'year': '2021', 'journal-title': 'Acta Pharmacol. Sin.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib19', 'doi-asserted-by': 'crossref', 'first-page': '6606', 'DOI': '10.1039/C7CP07869B', 'article-title': 'Computational identification of the binding mechanism of a triple ' 'reuptake inhibitor amitifadine for the treatment of major depressive ' 'disorder', 'volume': '20', 'author': 'Xue', 'year': '2018', 'journal-title': 'Phys. Chem. Chem. Phys.'}, { 'issue': '1', 'key': '10.1016/j.compbiomed.2022.105552_bib20', 'doi-asserted-by': 'crossref', 'first-page': '90', 'DOI': '10.1016/j.jtcme.2021.09.001', 'article-title': 'The dual role of phytochemicals on SARS-CoV-2 inhibition by targeting ' 'host and viral proteins', 'volume': '12', 'author': 'Singh', 'year': '2021', 'journal-title': 'J. Tradit., Complementary Altern. Med.'}, { 'issue': '8', 'key': '10.1016/j.compbiomed.2022.105552_bib21', 'doi-asserted-by': 'crossref', 'first-page': '3917', 'DOI': '10.1021/acs.jcim.1c00355', 'article-title': 'Structure-based discovery of novel nonpeptide inhibitors targeting ' 'SARS-CoV-2 Mpro', 'volume': '61', 'author': 'Yang', 'year': '2021', 'journal-title': 'J. Chem. Inf. Model.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib22', 'first-page': '1', 'article-title': 'Phytochemicals as potential drug candidates for targeting SARS CoV 2 ' 'proteins, an in silico study', 'author': 'Nag', 'year': '2021', 'journal-title': 'Virus. Dis.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib23', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1111/cbdd.13847', 'article-title': 'Computational design and modeling of nanobodies toward SARS‐CoV‐2 ' 'receptor binding domain', 'volume': '98', 'author': 'Yang', 'year': '2021', 'journal-title': 'Chem. Biol. Drug Des.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib24', 'unstructured': 'GISAID - Initiative n.d. https://www.gisaid.org/(accessed January 27, ' '2022).'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib25', 'doi-asserted-by': 'crossref', 'first-page': 'W229', 'DOI': '10.1093/nar/gkx439', 'article-title': 'SDM: a server for predicting effects of mutations on protein stability', 'volume': '45', 'author': 'Pandurangan', 'year': '2017', 'journal-title': 'Nucleic Acids Res.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib26', 'doi-asserted-by': 'crossref', 'first-page': '1071', 'DOI': '10.1016/j.str.2020.06.006', 'article-title': 'Performance and its limits in rigid body protein-protein docking', 'volume': '28', 'author': 'Desta', 'year': '2020', 'journal-title': 'Structure'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib27', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1080/14786419.2021.1925894', 'article-title': 'Computational and experimental insights on the interaction of ' 'artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike ' 'protein receptor-binding domain (RBD)', 'author': 'Ribaudo', 'year': '2021', 'journal-title': 'Nat. Prod. Res.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib28', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2020.01664', 'article-title': 'Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing ' 'using in silico structure-based virtual screening approach', 'volume': '11', 'author': 'Choudhary', 'year': '2020', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib29', 'doi-asserted-by': 'crossref', 'first-page': '206', 'DOI': '10.1016/j.ins.2014.08.002', 'article-title': 'A dynamic niching genetic algorithm strategy for docking highly ' 'flexible ligands', 'volume': '289', 'author': 'Magalhães', 'year': '2014', 'journal-title': 'Inf. Sci.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib30', 'doi-asserted-by': 'crossref', 'first-page': '2418', 'DOI': '10.1002/jcc.26011', 'article-title': 'More bang for your buck: improved use of GPU nodes for GROMACS 2018', 'volume': '40', 'author': 'Kutzner', 'year': '2019', 'journal-title': 'J. Comput. Chem.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib31', 'doi-asserted-by': 'crossref', 'first-page': '1355', 'DOI': '10.1107/S0907444904011679', 'article-title': 'PRODRG: a tool for high-throughput crystallography of protein-ligand ' 'complexes', 'volume': '60', 'author': 'Schüttelkopf', 'year': '2004', 'journal-title': 'Acta Crystallogr. Sect. D Biol. Crystallogr.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib32', 'doi-asserted-by': 'crossref', 'first-page': '1951', 'DOI': '10.1021/ci500020m', 'article-title': 'g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations', 'volume': '54', 'author': 'Kumari', 'year': '2014', 'journal-title': 'J. Chem. Inf. Model.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib33', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.lfs.2021.119774', 'article-title': 'Evolutionary selectivity of amino acid is inspired from the enhanced ' 'structural stability and flexibility of the folded protein', 'volume': '281', 'author': 'Rao', 'year': '2021', 'journal-title': 'Life Sci.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib34', 'doi-asserted-by': 'crossref', 'first-page': '423', 'DOI': '10.1017/S0033583500002845', 'article-title': 'An analysis of packing in the protein folding problem', 'volume': '26', 'author': 'Richards', 'year': '1993', 'journal-title': 'Q. Rev. Biophys.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib35', 'doi-asserted-by': 'crossref', 'first-page': '1072', 'DOI': '10.1006/jmbi.1996.0697', 'article-title': 'The crystal structure of a hyperthermophilic archaeal TATA-box binding ' 'protein', 'volume': '264', 'author': 'DeDecker', 'year': '1996', 'journal-title': 'J. Mol. Biol.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib36', 'doi-asserted-by': 'crossref', 'first-page': '409', 'DOI': '10.1038/s41579-021-00573-0', 'article-title': 'SARS-CoV-2 variants, spike mutations and immune escape', 'volume': '19', 'author': 'Harvey', 'year': '2021', 'journal-title': 'Nat. Rev. Microbiol.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib37', 'doi-asserted-by': 'crossref', 'first-page': '2362', 'DOI': '10.1016/j.cell.2021.02.042', 'article-title': 'SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune ' 'escape', 'volume': '184', 'author': 'Li', 'year': '2021', 'journal-title': 'Cell'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib38', 'doi-asserted-by': 'crossref', 'first-page': '477', 'DOI': '10.1016/j.chom.2021.01.014', 'article-title': 'Identification of SARS-CoV-2 spike mutations that attenuate monoclonal ' 'and serum antibody neutralization', 'volume': '29', 'author': 'Liu', 'year': '2021', 'journal-title': 'Cell Host Microbe'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib39', 'doi-asserted-by': 'crossref', 'first-page': '616', 'DOI': '10.1038/s41586-021-03324-6', 'article-title': 'mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants', 'volume': '592', 'author': 'Wang', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib40', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.12998/wjcc.v10.i1.1', 'article-title': 'Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, ' 'transmission, and vaccine resistance', 'volume': '10', 'author': 'Ren', 'year': '2022', 'journal-title': 'World J Clin Cases'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib41', 'doi-asserted-by': 'crossref', 'first-page': '2043', 'DOI': '10.1038/s41598-021-81462-7', 'article-title': 'Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of ' 'human cell membrane: insights from computational studies', 'volume': '11', 'author': 'Jena', 'year': '2021', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib42', 'doi-asserted-by': 'crossref', 'first-page': '6900', 'DOI': '10.3390/molecules26226900', 'article-title': 'Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells ' 'through multiple antiviral mechanisms', 'volume': '26', 'author': 'Marín-Palma', 'year': '2021', 'journal-title': 'Molecules'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib43', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.micpath.2021.104954', 'article-title': 'Phytochemicals present in Indian ginseng possess potential to inhibit ' 'SARS-CoV-2 virulence: a molecular docking and MD simulation study', 'volume': '157', 'author': 'Kushwaha', 'year': '2021', 'journal-title': 'Microb. Pathog.'}, { 'key': '10.1016/j.compbiomed.2022.105552_bib44', 'doi-asserted-by': 'crossref', 'first-page': '135', 'DOI': '10.1007/s12013-017-0821-6', 'article-title': 'Identification of phytochemicals targeting c-met kinase domain using ' 'consensus docking and molecular dynamics simulation studies', 'volume': '76', 'author': 'Aliebrahimi', 'year': '2018', 'journal-title': 'Cell Biochem. Biophys.'}], 'container-title': 'Computers in Biology and Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0010482522003444?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0010482522003444?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T09:51:10Z', 'timestamp': 1651398670000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0010482522003444'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7]]}, 'references-count': 44, 'alternative-id': ['S0010482522003444'], 'URL': 'http://dx.doi.org/10.1016/j.compbiomed.2022.105552', 'relation': {}, 'ISSN': ['0010-4825'], 'subject': ['Health Informatics', 'Computer Science Applications'], 'container-title-short': 'Computers in Biology and Medicine', 'published': {'date-parts': [[2022, 7]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) ' 'Omicron, an in silico study', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Computers in Biology and Medicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.compbiomed.2022.105552', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '105552'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit